Drug Type Small molecule drug |
Synonyms AT-101 (Ascenta Therapeutics), AT101, AT101(Ascenta Therapeutics) |
Target |
Action inhibitors, stimulants |
Mechanism Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors), Apoptosis stimulants |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC32H34O10 |
InChIKeyNIOHNDKHQHVLKA-UHFFFAOYSA-N |
CAS Registry866541-93-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Endometriosis | China | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma Multiforme | Phase 2 | China | 20 Oct 2017 | |
Non-Small Cell Lung Cancer | Phase 2 | China | 02 Jun 2012 | |
Non-Small Cell Lung Cancer | Phase 2 | China | 02 Jun 2012 | |
Laryngeal Neoplasms | Phase 2 | United States | 31 Mar 2012 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | United States | 01 Jun 2010 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | United States | 01 Sep 2009 | |
Glioma | Phase 2 | United States | 28 Feb 2009 | |
Recurrent Non-Small Cell Lung Cancer | Phase 2 | United States | 01 Sep 2007 | |
Recurrent Non-Small Cell Lung Cancer | Phase 2 | Russia | 01 Sep 2007 | |
Recurrent Non-Small Cell Lung Cancer | Phase 2 | Ukraine | 01 Sep 2007 |
Phase 1/2 | 5 | thkhfzensz(utxbcxdmjp) = mgtearjzmh sqwkstemmm (tuqecgelbw, bxsbegzwwv - asgmztvogs) View more | - | 16 Jun 2020 | |||
Phase 1 | 24 | vewdbachrk(ilnbqlwizm) = the MTD was not determined qgspcmwkum (zmokptjnoi ) | Negative | 01 Jun 2020 | |||
Phase 1 | 10 | jbnownktsu(gsnteigfor) = at 20 mg daily dose of AT-101 with 25 mg of R and 40 mg weekly :1 pt with febrile neutropenia and neutropenia lasting 9 days and 1 pt with thrombocytopenia lasting 8 days ctakpaprtv (emjshtbwhs ) View more | Positive | 13 Nov 2019 | |||
Phase 2 | 29 | knevbvnxsk(tltolexfgo) = gxqaerzqyj jckdshvlgw (dihtwiihzt ) | Negative | 01 Aug 2019 | |||
Phase 2 | 56 | laboratory biomarker analysis+R-(-)-gossypol acetic acid | mplshmakrz(qfxwptxiab) = kjtqcvzrzn dejzenxmar (hdthvouspb, deikdvymps - ocxddtttiu) View more | - | 12 Jul 2017 | ||
Phase 2 | 6 | kmjjbwqonf = hyuzwygnbf yiapbsqvaj (nljorxuzcn, yhsnjtpfyg - edvnmaiuxr) View more | - | 20 Nov 2015 | |||
Phase 2 | 35 | noqnjamlqu = gihfsqrjvo vlxacvzrvo (zfknpxcydt, bdwcujcouv - rbaxtxnzli) View more | - | 23 Jul 2015 | |||
Phase 2 | 55 | jklceyakkk = rpyuawvmon djjkgezgpy (bjxmmugtag, vfwnjsbvnz - gywcbvjnbi) View more | - | 18 Dec 2014 | |||
Phase 2 | 29 | bneblniway = kehgrcqohp jwfqkezxpy (mqsenuvcec, dfjzynbcpm - rccszapqps) View more | - | 21 Feb 2014 | |||
Phase 2 | 15 | pharmacological study+R-(-)-gossypol acetic acid | nmcnvdxceu = cvgdbktvjz gicbpspgqw (ecwdrexlhu, rvqluryaki - mudehpwnai) View more | - | 21 Mar 2013 |